# Concert Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/concert-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Lexington, US
- Website: www.concertpharma.com
- Total disclosed funding: $95M
- Latest round: Series C (Apr 3, 2008)
- Investors on record: 12

## About

Concert Pharmaceuticals, Inc. specializes in developing innovative therapeutics using its proprietary DCE Platform to enhance existing drugs, focusing on improving efficacy and safety while addressing unmet medical needs in various therapeutic areas.Founded in 2006 and headquartered in Lexington, US, Concert Pharmaceuticals, Inc. is engaged in creating novel pharmaceutical solutions. The company, led by CEO Roger Tung, has undergone significant funding activities, including a Trade Sale in 2015 that raised USD 576.00 mn from Sun Pharmaceutical Industries Limited. Concert has completed a total of 16 deals, with the most recent deal on March 19, 2015, marking a pivotal moment for the firm.Concert Pharmaceuticals focuses on developing innovative therapeutics that utilize its proprietary DCE Platform (Deuterated Chemical Entity) to create deuterated compounds. These products aim to improve efficacy and safety and reduce side effects of existing drugs, particularly in psychiatry, dermatology, and inflammatory diseases, ultimately enhancing patient outcomes and adherence. The company targets the U.S. market and is also exploring opportunities in Europe and Asia, catering to healthcare providers, specialty pharmacies, and patients requiring specific therapeutic interventions.In the most recent fiscal year of 2021, Concert Pharmaceuticals reported revenue of USD 32.58 mn and an EBITDA of USD -76.03 mn. The company generates revenue through strategic partnerships and collaborations with major pharmaceutical firms, relying on licensing agreements that include milestone payments and royalties based on sales of its proprietary products.Moving forward, Concert Pharmaceuticals aims to leverage its recent funding of USD 576.00 mn to advance early clinical efficacy studies specifically targeting HIV-positive patients. The company is focused on expanding its product pipeline with upcoming launches designed to meet critical therapeutic demands. Additionally, Concert is seeking to penetrate further into international markets, particularly in Europe and Asia, in the coming years.

## Funding rounds

- Series C, Apr 3, 2008, $37M — Flagship Pioneering, Mediphase Venture Partners, TVM Capital Life Science, Three Arch Partners, Skyline Ventures, Brookside Capital Partners, SR One, Greylock Partners, New Leaf Venture Partners, Adage Capital Management, QVT Financial, Westfield Contributory Retirement System
- Series B, Nov 27, 2006, $48M — Flagship Pioneering, TVM Capital Life Science, Three Arch Partners, Skyline Ventures, Brookside Capital Partners, Greylock Partners, New Leaf Venture Partners, QVT Financial
- Series A, May 17, 2006, $10M — TVM Capital Life Science, Three Arch Partners, Skyline Ventures, Greylock Partners, QVT Financial

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B, Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C
- Greylock Partners (https://capitalatlas.ai/funds/greylock-partners) — Series A, Series B, Series C
- QVT Financial — Series A, Series B, Series C
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B, Series C
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Mediphase Venture Partners (https://capitalatlas.ai/funds/mediphase-venture-partners) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Adage Capital Management — Series C
- Westfield Contributory Retirement System — Series C